KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$23.4 million.

  • Amneal Pharmaceuticals' Tax Provisions fell 73707.04% to -$23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 5261.65%. This contributed to the annual value of $18.9 million for FY2024, which is 12235.29% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Tax Provisions stood at -$23.4 million, which was down 73707.04% from $16.1 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Tax Provisions registered a high of $16.1 million during Q2 2025, and its lowest value of -$23.4 million during Q3 2025.
  • Moreover, its 5-year median value for Tax Provisions was $3.7 million (2024), whereas its average is $2.7 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first plummeted by 97500.0% in 2022, then surged by 1583043.48% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Tax Provisions (Quarter) stood at $4.1 million in 2021, then plummeted by 143.9% to -$1.8 million in 2022, then surged by 651.72% to $9.9 million in 2023, then crashed by 45.02% to $5.5 million in 2024, then crashed by 527.75% to -$23.4 million in 2025.
  • Its Tax Provisions stands at -$23.4 million for Q3 2025, versus $16.1 million for Q2 2025 and $12.9 million for Q1 2025.